Pfizer has fleshed out some more of the details of its wide-ranging cost-cutting drive announced last month, revealing that around 500 jobs will go in the UK, including at
Bayer’s new chief executive Bill Anderson has launched a “re-design” of Bayer that will see layers of management stripped out by the end of next year, with “95% of the dec
A positive clinical trial is usually a signal for a biotech startup to press the accelerator on its spending, but Kronos Bio is taking a different tack.
Sangamo Therapeutics has announced another wave of job losses and a plan to license out two lead clinical programmes as it tries to reinvent itself as a neurology-focused
Gene-editing company Beam Therapeutics has shifted into reverse, slashing staff and R&D programmes after a period of expansion since its public debut in 2020.
Netherlands gene therapy company uniQure has said it will shed 20% of its workforce, around 114 jobs, and slash its R&D projects in an effort to extend its cash reserv